Löwhagen O, Rak S
J Allergy Clin Immunol. 1985 Apr;75(4):460-7. doi: 10.1016/s0091-6749(85)80018-x.
Repeated bronchial histamine challenges before, during, and after the birch pollen season were performed in 22 allergic patients with bronchial hyperreactivity (BHR) treated for 6 wk with sodium cromoglycate (SCG), 20 mg, four times a day, or placebo in a double-blind, randomized group comparison. Clinical assessments of the asthmatic symptom score and peak expiratory flow revealed less symptoms and less use of bronchodilators in the SCG group. Responsiveness to histamine was significantly increased in the placebo group after 14 days with high pollen counts. After the season there was an immediate return to preseasonal value. There was no change in responsiveness in the SCG group, demonstrating significant protection against pollen-induced increase of BHR. The results support the hypothesis that inhibition of mediator release, which is demonstrated for SCG, leads to a reduction of the nonspecific BHR.
在桦树花粉季节之前、期间和之后,对22名患有支气管高反应性(BHR)的过敏患者进行了重复的支气管组胺激发试验。这些患者被随机分为两组,一组接受色甘酸钠(SCG)治疗,20毫克,每日四次,共6周;另一组接受安慰剂治疗,采用双盲法进行组间比较。对哮喘症状评分和呼气峰值流速的临床评估显示,SCG组的症状较少,支气管扩张剂的使用也较少。在花粉计数高的14天后,安慰剂组对组胺的反应性显著增加。季节过后,反应性立即恢复到季前水平。SCG组的反应性没有变化,表明对花粉诱导的BHR增加有显著的保护作用。结果支持这样的假设,即SCG所证明的介质释放抑制导致非特异性BHR的降低。